en el tratamiento con CellCept - Roche Trasplantes

Aspectos prácticos
en el tratamiento con CellCept ®
6
Zanker B, Schneeberger H, Rothenpieler U, Hillebrand G, Illner
WD, Theodorakis I et al. CellCept ® -based, cyclosporine-free induction
and maintenance immunosuppression: first-3-months
analysis of efficacy and safety in two cohorts of renal allograft recipients.
Transplantation 1998; 66: 44-9.
7
Schlitt HJ, Barkmann A, Boker KH, Schmidt HH, Emmanouilidis
N, Rosenau J et al. Replacement of calcineurin inhibitors with
CellCept ® in liver-transplant patients with renal dysfunction: a randomised
controlled study. Lancet 2001; 357: 587-91.
2.- Ajuste de los inhibidores de la calcineurina (ciclosporina,
tacrolimus)
1
Danovitch GM et al. Immunosuppressant-induced metabolic toxicities.
Transplant Rev 2000; 14: 65-81.
2
De Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive
drugs: long-term consequences and challenges
for the future. Am J Kidney Dis 2000; 35: 333-46.
3
Weir MR, Ward MT, Blahut SA, Klassen DK, Cangro CB, Bartlett ST
et al. Long-term impact of discontinued or reduced calcineurin inhibitor
in patients with chronic allograft nephropathy after the first year
posttransplantation. Transplant Proc 2001 33 (Suppl 4): 19S-28S.
4
Weir MR. Methods and outcomes of calcineurin inhibitor reduction
or withdrawal in patients with chronic allograft nephropathy
after the first year posttransplantation. Transplant Proc 2001;
33(Suppl 4): 19S-28S.
5
Land W, Schneeberger H, Weiss M, Ege T, Stumpfig L. CellCept ®
monotherapy; an optimal, safe, and efficacious immunosuppressive
maintenance regimen in kidney transplant patients. Transplant
Proc 2001; 33 (Suppl 4): 29S-35S.
6
Zanker B, Schneeberger H, Rothenpieler U, Hillebrand G, Illner
WD, Theodorakis I et al. CellCept ® -based, cyclosporine-free induction
and maintenance immunosuppression: first-3-months
analysis of efficacy and safety in two cohorts of renal allograft recipients.
Transplantation 1998; 66: 44-9.
16
7
Dudley et al. A multicentre randomised controlled study investigating
the effect of CellCept ® (MMF) on renal function after cyclosporin
A (CsA) withdrawal in renal transplant patients with a “creeping
creatinine”: An interin analysis of an ongoing study. American
Society for Transplantation Annual Meeting, Chicago, May
11-16, 2001. Am J Transplant 2001; 1(Suppl 1): abstr 194.